Exact Sciences Announces Board Member Retirement
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)
United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been add
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
10 Best Performing Biotech ETFs in 2024
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook
Sector Update: Health Care Stocks Advance Premarket Monday
Health care stocks were advancing in premarket activity Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.6% and the iShares Biotechnology ETF (IBB) was 0.3% higher recently. Neumora Th
Exact Sciences: Bloomer to Succeed Jeff Elliott Following Transition Period >EXAS
Exact Sciences: Bloomer to Succeed Jeff Elliott Following Transition Period >EXAS
Exact Sciences Names Aaron Bloomer As New Chief Financial Officer >EXAS
Exact Sciences Names Aaron Bloomer As New Chief Financial Officer >EXAS
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Here's Why Exact Sciences Corporation (EXAS) Declined in Q1
Exact Sciences Announces Debt Exchange Transaction
Myriad Genetics (MYGN) Announces Favorable Research Results
Zacks Investment Ideas Feature Highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
Exact Sciences: To Issue to Holders $620.7M of New Series of 1.75% Convertible Senior Notes Due 2031 in Exchange for Retirement of $359.7M of Holders' Existing Notes, and Payment to Co of About $266.8M Cash >EXAS
Exact Sciences: To Issue to Holders $620.7M of New Series of 1.75% Convertible Senior Notes Due 2031 in Exchange for Retirement of $359.7M of Holders' Existing Notes, and Payment to Co of About $266.8
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
3 Buy-Rated Stocks Flexing Relative Strength
No Data